摘要
依托咪酯是在2022年流行并迅速泛滥的临床麻醉药物,并于2023年10月被迅速列管.列管后,对依托咪酯的管控将按照毒品标准进行.以新列管的依托咪酯为切入点,系统总结了依托咪酯及临床衍生物的药理功能,梳理了依托咪酯及衍生物的临床检测分析及司法实践和司法鉴定中的检测技术规范.针对"以药代毒"这一新的毒情形势,从临床麻醉药物和精神药物的溯源、毒品同系物衍生物的监测、毒品合成原料和设备的备案、新型流毒载体的管控、检测技术和方法的标准化五个方面提出建议,以期为遏制以依托咪酯为代表的临床合法药物被非法滥用及毒品的科学管理和有效打击提供思路和借鉴.
Abstract
Etomidate is a clinical anesthetics that became popular and rapidly spread in 2022,and was quickly listed in October 2023.After listing,the control of etomidate will be carried out according to narcotic standards.Starting from the newly listed etomidate,this review systematically summarizes the pharmacological functions of etomidate and its clinical derivatives,and outlines the clinical testing and analysis of etomidate and its derivatives,as well as the testing technical specifications in forensic practice and forensic appraisal.Responding to the new drug abuse situation as"substituting drugs for narcotics",work suggestions are proposed from five aspects:tracing the origins of clinical anesthetics and psychotropic drugs,the monitoring of derivatives of narcotics,the filing of raw materials and equipments for narcotics synthesis,the control of new types of narcotics carriers,and the standardization of analyzing methods.The aim is to provide work suggestions and reference for curbing the illegal abuse of clinically legal drugs represented by etomidate,as well as scientific management and effective crackdown on narcotics.
维普
万方数据